Skip to main content
Premium Trial:

Request an Annual Quote

Quantum Biosystems Raises ¥1B in Series C Financing Round

NEW YORK (GenomeWeb) – Quantum Biosystems said today that it has closed a ¥1 billion ($8.8 million) Series C financing round through the sale of preferred stock to Japanese venture capital company SBI Investment.

Quantum Biosystems, which was founded in January 2013 as a spinout of Osaka University, is developing a single-molecule sequencing technology intended to significantly reduce the cost and improve the accuracy of sequencing. The technology measures tunneling currents from DNA bases as the molecule passes by a sub-nanometer gap, and the company said that it has achieved resolution of one base pair with its method.

Quantum Biosystems said it plans to use the new funding to continue development of its sequencing technology by hiring additional scientists and expanding its academic and industry collaborations. It also said that it is specifically conducting research into using massively parallel nano-electrodes on a silicon device to detect current facilitated by electron tunneling and hopping.

The company last completed a funding round in 2015 for ¥2.4 billion.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.